The Insight Partners published latest research report on “Influenza Vaccines Market Size Report, Share, Trends, Growth, Demand & Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group”, the global market size is projected to reach USD 12,272.49 million by 2028 from USD 7,478.53 million in 2021
The Insight Partners published latest research report on “Influenza Vaccines Market Size Report, Share, Trends, Growth, Demand & Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group”, the global market size is projected to reach USD 12,272.49 million by 2028 from USD 7,478.53 million in 2021. The market is estimated to grow with a CAGR of 7.4% from 2022 to 2028.
Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00004070
Growth Strategies by the Key Players Operating in the Influenza Vaccines Market:
July -2022: The US Food and Drug Administration (FDA) approved Sanofi’s licensure request for vaccine approval for the upcoming 2022-2023 flu season, including Fluzone High-Dose Quadrivalent (Influenza Vaccine), Flublok Quadrivalent (Influenza Vaccine), and Fluzone Quadrivalent (Influenza Vaccine). This approval comes on the heels of the CDC’s Advisory Committee on Immunization Practices (ACIP) preferential recommendation for adults 65+ including Fluzone High-Dose Quadrivalent and Flublok Quadrivalent.
June -2022: Moderna, Inc. announced the first participants had been dosed in a Phase 3 study of the Company’s seasonal influenza vaccine candidate (mRNA-1010). The trial is expected to enroll approximately 6,000 adults in Southern Hemisphere countries.
March-2022: Seqirus confirmed that its cell-based seasonal influenza vaccine, Flucelvax Quad [quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell cultures)] has been approved by the Therapeutic Goods Administration (TGA) for children aged two years and older. The four-strain vaccine is the first and only cell-based influenza vaccine available in Australia, approved by the TGA for use in adults and children two years of age and older.
July -2022: GSK announced an agreement with the Government of Canada for pandemic and seasonal influenza vaccines to help protect Canadian adults and children. The four-year agreement, spanning through March 2026, includes the supply of as many as 80 million doses of Arepanrix (adjuvanted pandemic influenza vaccine) in the event of an influenza pandemic(s) and a minimum of 4 million doses per year of Flulaval Tetra (seasonal influenza vaccine).
October-2022: Interim results from the first co-administration descriptive study of Sanofi’s Fluzone High-Dose Quadrivalent vaccine with Moderna’s COVID-19 mRNA investigational booster dose show that the administration of the vaccines at the same visit had similar immunogenicity responses and a similar safety and tolerability profile compared to each vaccine administered individually.
Influenza virus causes flu which is a contagious respiratory illness that infects nose, throat and lungs. It can mild or severe and sometimes may lead to death. Flu vaccination every year can help in preventing flu. However, this can be deadly, especially in high-risk groups. Aged population, pregnant women and people with one or more chronic disease or with weak immune systems are at high risk. Influenza vaccines/flu shots protect against the four influenza viruses’ subtypes that are most common. Most of the influenza vaccines are “flu shots” given with a needle, usually in the arm, but nasal spray flu vaccine are also available.
Directly Purchase Premium Copy of Influenza Vaccines Market Growth Report (2022-2028) at: https://www.theinsightpartners.com/buy/TIPRE00004070
Global Influenza Vaccines Market Share Report, Segmentations, Regional & Country Scope:
| Report Coverage | Details |
| Market Size Value in | USD 7,478.53 Million in 2021 |
| Market Size Value by | USD 12,272.49 Million by 2028 |
| Growth rate | CAGR of 7.4% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2021 |
| No. of Pages | 209 |
| No. of Tables | 138 |
| No. of Charts & Figures | 80 |
| Historical data available | Yes |
| Segments covered | Vaccine Type, Virus Type, Technology, Route of Administration, and Target Group |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Companies Covered | Moderna, SEQIRUS, Sanofi, GlaxoSmithKline plc., Hualan Biological Engineering Inc., Emergent BioSolutions Inc., Mitsubishi Chemical Group Corporation, Serum Institute of India Pvt. Ltd, MYLAN N.V., AstraZeneca |
Browse key market insights spread across 209 pages with 138 list of tables & 80 list of figures from the report, “Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), Route of Administration (Injection and Nasal Spray), and Target Group (Infants, Children, Adults, and Elderly)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/influenza-vaccines-market
Key factors that are driving the growth of this market are the increase in government support to promote influenza vaccination and increasing investment by top market players and governments are expected to drive the market during the forecast period. However, high cost of vaccine development hampers the influenza vaccines market growth.
The governments of various states are supporting the promotional activities of vaccination program. For instance, the Australian government gives a free seasonal influenza vaccine to those at risk of influenza-related complications through the National Immunization Program (NIP). By 2022, enough vaccines have been given to cover all risk groups eligible for a government-funded flu vaccine through the NIP.
Below are a few more instances supporting the government support for influenza vaccination:
In July 2022, Public Services and Procurement Minister Filomena Tassi and Health Minister Jean-Yves Duclos announced that the Government of Canada had signed a new contract with GlaxoSmithKline (GSK) to support a sustainable influenza pandemic readiness. The Government of Canada maintains pandemic influenza vaccine preparedness in the event of an influenza pandemic.
In July 2022, Health Minister Audrey Gordon and Long-term Care Minister Scott Johnston announced that the Manitoba government would expand the high-dose flu vaccine eligibility to include all adults aged 65 and over to ensure more Manitoba people are protected against influenza.
• The Victorian government received a grant and reimbursement program to help GPs and pharmacies improve access and uptake of the influenza vaccines by June and July 2022.
Speak To Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00004070
In June 2022, The New Zealand government expanded the access to free flu vaccines, with an additional 800,000 New Zealanders eligible from July 1, 2022. Children aged 3 to 12 years and people with severe mental health or addiction problems can now get a free dose of the flu vaccines.
• Taiwan’s Centers for Disease Control (Taiwan CDC), and the Ministry of Health and Welfare, organized a media event, titled “Let’s Stay Healthy Together” to kick off the 2021 government-funded influenza vaccination program. At the event, Director General Chou, Ambassador Tan, and Hsin Chiang were the first to be vaccinated to encourage eligible people to receive government-funded flu vaccines to get their flu vaccinations as soon as possible following the program.
In September 2019, US President Donald Trump signed an executive order to promote the development of better vaccines to protect against seasonal flu and the potential for pandemic flu outbreaks.
In Oct 2021, with flu season approaching, the Provincial Government was encouraging all Newfoundlanders and Labradorians to get a flu shot in the year 2021. Starting October 25, 2021, the Regional Health Authorities (RHAs) have begun hosting free flu vaccination clinics. People can also get the vaccine through their family doctor or local pharmacy. Thus, increasing government support to promote influenza vaccination worldwide is driving the influenza vaccines market.
International Trade Administration (ITA), Farmindustria-Bain & Company, EFPIA member associations, World Health Organization (WHO), Business Monitor International (BMI), Department of Emergency Medicine, and Indian Journal of Medical Sciences are among the primary and secondary sources referred to while preparing the report on the influenza vaccines market.
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Influenza Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Influenza Antiviral Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Rapid Influenza Diagnostic Tests (RIDT) Market Forecast to 2028 - COVID-19 Impact and Global Analysis
General Influenza Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Canine Influenza Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Pandemic Influenza Vaccine Market Forecast to 2028 - COVID-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/influenza-vaccines-market